Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBCNovo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial ReutersNovo Nordisk Stock Plunges and Eli Lilly Jumps. It's Because of This Weight-Loss Drug Trial. Barron'sNovo Nordisk Trial Flop Ripples Through Denmark's Stock Market Bloomberg